Skip to main content

Peer Review reports

From: Clinical factors associated with shorter durable response, and patterns of acquired resistance to first-line pembrolizumab monotherapy in PD-L1-positive non-small-cell lung cancer patients: a retrospective multicenter study

Original Submission
11 Nov 2020 Submitted Original manuscript
25 Nov 2020 Author responded Author comments - Kazutaka Hosoya
Resubmission - Version 2
25 Nov 2020 Submitted Manuscript version 2
22 Feb 2021 Author responded Author comments - Kazutaka Hosoya
16 Jan 2021 Reviewed Reviewer Report
23 Jan 2021 Reviewed Reviewer Report
Resubmission - Version 3
22 Feb 2021 Submitted Manuscript version 3
11 Mar 2021 Author responded Author comments - Kazutaka Hosoya
8 Mar 2021 Reviewed Reviewer Report
23 Feb 2021 Reviewed Reviewer Report
Resubmission - Version 4
11 Mar 2021 Submitted Manuscript version 4
13 Mar 2021 Author responded Author comments - Kazutaka Hosoya
Resubmission - Version 5
13 Mar 2021 Submitted Manuscript version 5
Publishing
16 Mar 2021 Editorially accepted
1 Apr 2021 Article published 10.1186/s12885-021-08048-4

You can find further information about peer review here.

Back to article page
\